Market Place
Sourcing Support
Recursion acquires two AI-based drug discovery companies in $87.5M deal
08 May 2023 //
ENDPTS
Corrected: Zevra CEO hits the exit as minority shareholder`s nominees
08 May 2023 //
ENDPTS
KemPharm Announces Corporate Name Change to Zevra Therapeutics
22 Feb 2023 //
GLOBENEWSWIRE
KemPharm Enhances Senior Management Team
31 Jan 2023 //
GLOBENEWSWIRE
KemPharm Issues Letter to Shareholders
24 Jan 2023 //
GLOBENEWSWIRE
KemPharm Partners with Hypersomnia Foundation for Sleep Disorder Research
18 Jan 2023 //
GLOBENEWSWIRE
KemPharm Announces Promotion of Sven Guenther to CSO and Christal Mickle to CPDO
11 Jan 2023 //
GLOBENEWSWIRE
KemPharm Announces Leadership Changes to Support its Rare Disease Company
09 Jan 2023 //
GLOBENEWSWIRE
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077
21 Dec 2022 //
GLOBENEWSWIRE
KemPharm Announces Appointment of Christopher Posner as New Independent Director
29 Nov 2022 //
GLOBENEWSWIRE
KemPharm Receives FDA Orphan Designation for Serdexmethylphenidate for (IH)
18 Nov 2022 //
GLOBENEWSWIRE
KemPharm Supports Niemann-Pick Awareness Month During October
04 Oct 2022 //
GLOBENEWSWIRE
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment
01 Sep 2022 //
GLOBENEWSWIRE
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
11 Aug 2022 //
GLOBENEWSWIRE
KemPharm Appoints N. Ochsner as VP, Investor Relations, Corporate Communications
09 Aug 2022 //
GLOBENEWSWIRE
KemPharm to Report Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting
26 Jul 2022 //
GLOBENEWSWIRE
Orphazyme completes sale of substantially to KemPharm
31 May 2022 //
GLOBENEWSWIRE
Orphazyme’s Sorry Story Ends In Fire Sale
19 May 2022 //
SCRIP
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
17 May 2022 //
BUSINESSWIRE
Orphazyme meme ends with $13M sale to satisfy bankruptcy court
17 May 2022 //
FIERCEBIOTECH
Orphazyme under In-Court-Restructuring to sell all assets to KemPharm
15 May 2022 //
GLOBENEWSWIRE
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme
15 May 2022 //
GLOBENEWSWIRE
KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
12 May 2022 //
GLOBENEWSWIRE
KemPharm to Present at Multiple Upcoming Investor Conferences
11 May 2022 //
GLOBENEWSWIRE
KemPharm Announces Submission of Investigational NDA for PII Trial of KP1077
05 May 2022 //
GLOBENEWSWIRE
KemPharm to Report First Quarter 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
KemPharm Begins Dosing in PI Trial of Cardiovascular Safety of SDX
19 Apr 2022 //
GLOBENEWSWIRE
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results
30 Mar 2022 //
GLOBENEWSWIRE
KemPharm to Participate in Maxim`s 2022 Virtual Growth Conference
24 Mar 2022 //
GLOBENEWSWIRE
KemPharm Announces Full Data Set from Higher-Dose SDX Phase 1 Trial
21 Mar 2022 //
GLOBENEWSWIRE
KemPharm Earns $1.975 M Fee from Corium Following FDA Approval of ADLARITY
16 Mar 2022 //
GLOBENEWSWIRE
KemPharm to Report Q4 and FY 2021 Results
10 Mar 2022 //
GLOBENEWSWIRE
KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
23 Feb 2022 //
GLOBENEWSWIRE
KemPharm Issues Letter to Shareholders Detailing Focus on CNS/Rare Disease
19 Jan 2022 //
GLOBENEWSWIRE
KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
12 Jan 2022 //
GLOBENEWSWIRE
KemPharm to Feature Research Involving Serdexmethylphenidate in Presentations
11 Jan 2022 //
GLOBENEWSWIRE
KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
20 Dec 2021 //
GLOBENEWSWIRE
KemPharm, Announces Top-Line Results from Clinical Trial Evaluating the Safety
14 Dec 2021 //
GLOBENEWSWIRE
KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20
13 Dec 2021 //
GLOBENEWSWIRE
KemPharm Announces AZSTARYS Clinical Data to be Featured in Poster Presentation
05 Nov 2021 //
GLOBENEWSWIRE
AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm
27 Oct 2021 //
GLOBENEWSWIRE
KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate
20 Oct 2021 //
GLOBENEWSWIRE
KemPharm Appoints Tamara A. Seymour to Board of Directors
18 Aug 2021 //
GLOBENEWSWIRE
KemPharm to Report Second Quarter 2021 Results
05 Aug 2021 //
GLOBENEWSWIRE
KemPharm U.S. Launch of Innovative ADHD Treatment AZSTARYS by Corium, Inc
21 Jul 2021 //
GLOBENEWSWIRE
KemPharm Issues Letter to Shareholders
16 Jun 2021 //
GLOBENEWSWIRE
KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering (SDX)
26 May 2021 //
GLOBENEWSWIRE
KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified Schedule IV
07 May 2021 //
GLOBENEWSWIRE
KemPharm Confirms Receipt of $10 Million Milestone for FDA Approval of AZSTARYS™
22 Apr 2021 //
GLOBENEWSWIRE
KemPharm Announces Amendment to Licensing Agreement with Gurnet
08 Apr 2021 //
GLOBENEWSWIRE
KemPharm Announces FDA Approval of AZSTARYS™
03 Mar 2021 //
GLOBENEWSWIRE
KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program
28 Jan 2021 //
GLOBENEWSWIRE
KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured
14 Jan 2021 //
GLOBENEWSWIRE
KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder
22 Dec 2020 //
GLOBENEWSWIRE
KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder
22 Dec 2020 //
GLOBENEWSWIRE
KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA
02 Dec 2020 //
GLOBENEWSWIRE
KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured
23 Oct 2020 //
GLOBENEWSWIRE
KemPharm Files Preliminary Proxy for Special Meeting of Stockholders
25 Sep 2020 //
GLOBENEWSWIRE
KemPharm Announces Issuance of Two Additional U.S. Patents KP415 and KP484
28 Jul 2020 //
GLOBENEWSWIRE
